# Accium Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accium-biosciences

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.acciumbio.com
- Total disclosed funding: $3M
- Latest round: Series A (Jan 6, 2006)
- Investors on record: 1

## About

Accium Biosciences specializes in innovative radiopharmaceutical solutions aimed at improving drug development and personalized medicine. They focus on enhancing treatment efficacy through precise targeting of therapies.Accium Biosciences operates as a biopharmaceutical company that develops radiopharmaceutical therapies. Founded in Seattle, US, it was established by Glenn Kawasaki who has a background in the biopharmaceutical industry. In January 2006, Accium raised USD 3.000 mn in Series A funding led by WRF Capital, marking a significant milestone in their financial growth. The company has completed one deal to date.Accium Biosciences provides a suite of radiopharmaceutical products aimed at enhancing the drug development process for clients in diverse industries. Their offerings include specialized radioproducts designed for use in clinical trials, which facilitate targeted drug delivery and improve patient outcomes. The company caters to various customers, from small biotech firms to large pharmaceutical corporations, operating in regions including North America, Europe, and Asia. Their continuous innovation in product development ensures they stay responsive to market demands and technological advancements.The company’s revenue model is primarily based on Business-to-Business (B2B) transactions, leveraging partnerships and contracts with clients. Accium’s primary offerings are structured under tiered pricing plans, allowing clients to select packages that fit their operational needs. These packages include standard, premium, and enterprise options, each designed to align with varying scales of service and utilization, thereby fostering long-term client relationships and stable revenue streams.Accium Biosciences plans to introduce new radiopharmaceutical products aimed at enhancing the precision of treatment options available in the market. The company is strategically targeting expansion into the European and Asian markets by late 2023, leveraging recent funding to support these initiatives. The USD 3.000 mn raised in the Series A round will be allocated towards developing new product lines and enhancing their operational infrastructure to facilitate market entry and growth.

## Funding rounds

- Series A, Jan 6, 2006, $3M — WRF Capital

## Investors

- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A